Patient description: A 3-day-old Asian female infant presents with jaundice that started a day ago. She was born at 38w3d of gestation, after an uncomplicated pregnancy. The family history is unremarkable. The baby is breastfed. Vital signs are reported as: axillary temperature: 36.3°C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 3.2 kg, length is 53 cm, and head circumference 36 cm. Her sclera are yellow and her body is icteric. No murmurs or any other abnormalities are detected in the heart and lung auscultation. Her liver and spleen are normal on palpation. Laboratory results are as follows: Serum total bilirubin: 21.02 mg/dL Direct bilirubin of 2.04 mg/dL AST: 37 U/L ALT: 20 U/L GGT: 745 U/L Alkaline phosphatase: 531 U/L Creatinine: 0.3 mg/dL Urea: 29 mg/dL Na: 147 mEq/L K: 4.5 mEq/L CRP: 3 mg/L Complete blood cell count within the normal range. She is diagnosed with uncomplicated neonatal jaundice that may require phototherapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-0.14,  Bronchopulmonary Dysplasia Neonatal infants who fulfil all of the following will be enrolled: 1. Subjects of postnatal age between 3 to 30 days. 2. Are male and female infants born at GA between 23 weeks to 29 weeks. The postmenstrual age of subject received UMC119-01 should be no more than PMA36 weeks. 3. Subjects with birth weight between 501g to 1249 g. 4. Have endotracheal tube in place as part of SoC for preterm infants with BPD at screening and on treatment visit (Day 0), and that they will have not been intubated for the purposes of this study. 5. A subject who is intubated and receiving mechanical ventilation with a fraction of inspired oxygen (FiO2) of 0.25 or greater at Screening. 6. A subject who has had either a deterioration or no change in the setting of mechanical ventilation within the 24 hours before trial enrollment. 7. Written informed consent has been provided by the subject's parents, legal guardians, or a legal representative, who agree to comply with all of the study procedures, including those in the long-term safety surveillance period  Neonatal infants who meet any of the following will be excluded: 1. Have a major congenital abnormality, including neurological (including anencephaly and similar malformations), hepatic, renal, cardiovascular abnormality (except for patent ductus arteriosus, PDA). 2. Have a known genetic syndrome. 3. Have a condition that makes them ineligible for participation in this study, as determined by the investigator. 4. Have C-reactive protein (CRP) >30 mg/L; or any infections including pneumonia, sepsis, or shock. 5. Have pre-existing severe intraventricular hemorrhage (IVH) (grade ≥3). 6. Have active pulmonary hemorrhage or air leak syndrome. 7. Have abnormal hepatic (AST, ALT >150 U/L or direct bilirubin >2 mg/dL or total bilirubin >15 mg/dL) or renal function (serum creatinine >1 mg/dL or oliguria). 8. Are known to be infected with HIV or CMV. 9. Are expected to have surgery within 24 hours prior to and/or after UMC119 01 instillation. 10. Are expected to receive any other intratracheal treatments, including surfactant within 72 hours prior to and/or after UMC119 01 instillation. 11. Are currently participating in any other interventional clinical trial